Loading
The first dedicated immunotherapy trial in NUT carcinoma, asking whether a PD-1 antibody can do anything in a cancer that chemotherapy rarely controls.
Case reports have described occasional responses of NUT carcinoma to checkpoint inhibitors despite its low mutation burden. This Northwestern University pilot gives cemiplimab to fifteen patients with metastatic or unresectable disease and measures safety and clinical activity. It is recruiting.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares NUT carcinoma (midline carcinoma with NUTM1 rearrangement) and the tag owner-request.
Shares NUT carcinoma (midline carcinoma with NUTM1 rearrangement) and the tag owner-request.
Shares NUT carcinoma (midline carcinoma with NUTM1 rearrangement) and the tag owner-request.
Shares Immune checkpoint inhibitors and the tag owner-request.
Shares Cemiplimab, Immune checkpoint inhibitors.
Shares Cemiplimab, Immune checkpoint inhibitors.
Shares Cemiplimab, Immune checkpoint inhibitors.
Shares Cemiplimab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/